These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3806307)

  • 1. Individualizing gentamicin dosage in patients with cystic fibrosis: limitations to pharmacokinetic approach.
    Hendeles L; Iafrate RP; Stillwell PC; Mangos JA
    J Pediatr; 1987 Feb; 110(2):303-10. PubMed ID: 3806307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily gentamicin dosing in pediatric patients without cystic fibrosis.
    McDade EJ; Wagner JL; Moffett BS; Palazzi DL
    Pharmacotherapy; 2010 Mar; 30(3):248-53. PubMed ID: 20180608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis.
    Bauer LA; Piecoro JJ; Wilson HD; Blouin RA
    Clin Pharm; 1983; 2(3):262-4. PubMed ID: 6883955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis.
    Mann HJ; Canafax DM; Cipolle RJ; Daniels CE; Zaske DE; Warwick WJ
    Pediatr Pulmonol; 1985; 1(5):238-43. PubMed ID: 4069813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a dosage individualization table for extended-interval gentamicin in neonates.
    Dersch-Mills D; Akierman A; Alshaikh B; Yusuf K
    Ann Pharmacother; 2012; 46(7-8):935-42. PubMed ID: 22739714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic adjustment of gentamicin dosing in horses with sepsis.
    Sojka JE; Brown SA
    J Am Vet Med Assoc; 1986 Oct; 189(7):784-9. PubMed ID: 3771340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis.
    Kearns GL; Hilman BC; Wilson JT
    J Pediatr; 1982 Feb; 100(2):312-8. PubMed ID: 7035640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between vancomycin dosage and serum trough vancomycin concentrations in pediatric patients with cystic fibrosis.
    Durham SH; Garza KB; Eiland LS
    Am J Health Syst Pharm; 2016 Jul; 73(13):969-74. PubMed ID: 27325878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized aminoglycoside dosage regimens in patients with cystic fibrosis.
    Delage G; Desautels L; Legault S; Lasalle R; Lapierre JG; Lamarre A; Masson P; Spier S
    Drug Intell Clin Pharm; 1988 May; 22(5):386-9. PubMed ID: 3391108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
    Staubes BA; Metzger NL; Walker SD; Peasah SK
    Pharmacotherapy; 2016 Jun; 36(6):623-30. PubMed ID: 27138730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.
    Inparajah M; Wong C; Sibbald C; Boodhan S; Atenafu EG; Naqvi A; Dupuis LL
    Pharmacotherapy; 2010 Jan; 30(1):43-51. PubMed ID: 20030472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of children for whom routine monitoring of aminoglycoside serum concentrations is not cost effective.
    Massey KL; Hendeles L; Neims A
    J Pediatr; 1986 Nov; 109(5):897-901. PubMed ID: 3095524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates.
    Hoff DS; Wilcox RA; Tollefson LM; Lipnik PG; Commers AR; Liu M
    Pharmacotherapy; 2009 Nov; 29(11):1297-305. PubMed ID: 19857147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian forecasting of gentamicin pharmacokinetics in pediatric intensive care unit patients.
    Kraus DM; Dusik CM; Rodvold KA; Campbell MM; Kecskes SA
    Pediatr Infect Dis J; 1993 Sep; 12(9):713-8. PubMed ID: 8414796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of gentamicin peak and trough concentrations from six extended-interval dosing protocols for neonates.
    Murphy JE
    Am J Health Syst Pharm; 2005 Apr; 62(8):823-7. PubMed ID: 15821275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictability of peak serum gentamicin concentration with dosage based on body surface area.
    Siber GR; Smith AL; Levin MJ
    J Pediatr; 1979 Jan; 94(1):135-8. PubMed ID: 758394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered gentamicin pharmacokinetics during the perioperative period.
    Kloth DD; Tegtmeier BR; Kong C; Akahoshi MP; Leach SH; Beatty JD; Zaia JA
    Clin Pharm; 1985; 4(2):182-5. PubMed ID: 3987217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
    Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
    Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine monitoring of gentamicin serum concentrations in pediatric patients with normal renal function is unnecessary.
    Logsdon BA; Phelps SJ
    Ann Pharmacother; 1997 Dec; 31(12):1514-8. PubMed ID: 9416390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
    Hennig S; Holthouse F; Staatz CE
    Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.